News | May 10, 2022
Sun gets 10 observations from USFDA for Halol facility
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
ICICI Direct gives a preview on the earnings narrative for Q3FY22
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Subscribe To Our Newsletter & Stay Updated
